BioXcel Therapeutics (BTAI)
(Delayed Data from NSDQ)
$0.64 USD
+0.01 (1.08%)
Updated Sep 18, 2024 04:00 PM ET
After-Market: $0.64 0.00 (0.44%) 7:58 PM ET
2-Buy of 5 2
F Value C Growth C Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
BTAI 0.64 +0.01(1.08%)
Will BTAI be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for BTAI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BTAI
BioXcel Therapeutics (BTAI) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
BioXcel Therapeutics, Inc. (BTAI) Reports Q2 Loss, Tops Revenue Estimates
BTAI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for BTAI
FMR LLC's Strategic Reduction in BioXcel Therapeutics Inc Shares
BioXcel Therapeutics Announces Initiation of SERENITY At-Home Pivotal Phase 3 Safety Trial of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
BioXcel Therapeutics announces initiation of SERENITY Phase 3 trial
Bioxcel Therapeutics (BTAI) Receives a Hold from Mizuho Securities
BioXcel Therapeutics, Inc. (BTAI) Q2 2024 Earnings Call Transcript